An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms The Approach Open Label Study
- Sponsors Ionis Pharmaceuticals
- 13 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2017 Time frame of primary endpoint has been changed from 52 Weeks to 117 Weeks.
- 04 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.